Cerebrospinal fluid biomarkers in the Longitudinal Early-onset Alzheimer's Disease Study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dage Jeffrey L, Eloyan Ani, Thangarajah Maryanne, Hammers Dustin B, Fagan Anne M, Gray Julia D, Schindler Suzanne E, Snoddy Casey, Nudelman Kelly N H, Faber Kelley M, Foroud Tatiana, Aisen Paul, Griffin Percy, Grinberg Lea T, Iaccarino Leonardo, Kirby Kala, Kramer Joel, Koeppe Robert, Kukull Walter A, La Joie Renaud, Mundada Nidhi S, Murray Melissa E, Rumbaugh Malia, Soleimani-Meigooni David N, Toga Arthur W, Touroutoglou Alexandra, Vemuri Prashanthi, Atri Alireza, Beckett Laurel A, Day Gregory S, Graff-Radford Neill R, Duara Ranjan, Honig Lawrence S, Jones David T, Masdeu Joseph C, Mendez Mario F, Musiek Erik, Onyike Chiadi U, Riddle Meghan, Rogalski Emily, Salloway Stephen, Sha Sharon J, Turner Raymond S, Wingo Thomas S, Wolk David A, Womack Kyle B, Carrillo Maria C, Dickerson Bradford C, Rabinovici Gil D, Apostolova Liana G, LEADS Consortium
Аннотация
METHODS: Cerebrospinal fluid (CSF) concentrations of Aβ1-40, Aβ1-42, total tau (tTau), pTau181, VILIP-1, SNAP-25, neurogranin (Ng), neurofilament light chain (NfL), and YKL-40 were measured by immunoassay in 165 LEADS participants. The associations of biomarker concentrations with diagnostic group and standard cognitive tests were evaluated.
RESULTS: Biomarkers were correlated with one another. Levels of CSF Aβ42/40, pTau181, tTau, SNAP-25, and Ng in EOAD differed significantly from cognitively normal and early-onset non-AD dementia; NfL, YKL-40, and VILIP-1 did not. Across groups, all biomarkers except SNAP-25 were correlated with cognition. Within the EOAD group, Aβ42/40, NfL, Ng, and SNAP-25 were correlated with at least one cognitive measure.
DISCUSSION: This study provides a comprehensive analysis of CSF biomarkers in sporadic EOAD that can inform EOAD clinical trial design.